Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2016 2 896 M
EBIT 2016 925 M
Net income 2016 735 M
Debt 2016 1 774 M
Yield 2016 0,34%
Sales 2017 3 651 M
EBIT 2017 1 174 M
Net income 2017 985 M
Debt 2017 929 M
Yield 2017 0,41%
P/E ratio 2016 22,75
P/E ratio 2017 16,99
EV / Sales2016 6,35x
EV / Sales2017 4,81x
Capitalization 16 626 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
03/21Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
2016 3SBIO : granted exclusive license of diabetes drugs
2016 3SBIO : AstraZeneca Ink Licensing Agreement
2016 3SBIO : gets nod for colorectal cancer drug clinical trial
2016 3SBIO INC. : (01530) says ITP drug get clinical trial approval
2016 3SBIO INC. : (01530) withdraws breast cancer drug application
2016 3SBIO : PEG-irinotecan Wins IND Approval From China FDA
2016 3SBIO : Bought CNY3.9bn Shares in CPGJ
2016 3SBIO : adds stake in CP Guojian Pharma at Rmb3.9bn
2016 3SBIO : Wins Financing for Further Equity Investment
2016 3SBIO : inks Rmb2.2bn term loan facility
More news
Sector news : Biopharmaceuticals
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
01/12 Investors in big pharma, biotech look to ride out Trump storm
More sector news : Biopharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 9,05  CNY
Spread / Average Target 38%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Zhenping Zhu Chief Scientific Officer, President-R&D
Dong Mei Su Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)0.00%2 410
BIOGEN INC0.41%61 954
CSL LIMITED0.67%34 463
ALEXION PHARMACEUTICAL..11.92%30 663
BIOMARIN PHARMACEUTICA..4.93%14 949
GRIFOLS SA3.71%13 296
More Results